Piperacetazine

Piperacetazine

Clinical data
Trade names	Actazine, Quide, Psymod
AHFS/Drugs.com	International Drug Names
Identifiers
IUPAC name 1-[10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]phenothiazin-2-yl]ethanone
CAS Number	3819-00-9  Y
PubChem CID	19675
ChemSpider	18533
UNII	KL6248WNW4
ChEBI	CHEBI:92293
ChEMBL	ChEMBL1584  Y
CompTox Dashboard (EPA)	DTXSID7023481
ECHA InfoCard	100.021.194
Chemical and physical data
Formula	C24H30N2O2S
Molar mass	410.58 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)c1ccc2Sc3ccccc3N(CCCN4CCC(CCO)CC4)c2c1
InChI InChI=InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3 Key:BTFMCMVEUCGQDX-UHFFFAOYSA-N

Piperacetazine (Quide) is an antipsychotic prodrug, most notably used for schizophrenia. ^[1] It is a phenothiazine derivative. Based on clinical trial data, it appears to have similar efficacy as chlorpromazine. However, very little research has been done since the 1970s, and it is not a commonly used drug today. ^[2]

Side effects

The side effect profile of piperacetazine is similar to that of other typical antipsychotics. The most common side effects of piperacetazine are dizziness, drowsiness, fainting, orthostatic hypotension, and extrapyramidal symptoms. Less common side effects include nausea, vomiting, bradycardia, euphoria, and headache. Rare side effects include leukopenia, thrombocytopenia, galactorrhea, amenorrhea, seizures, urinary retention, and jaundice. ^[2]

References

1. Rada RT, Donlon PT (February 1974). "Piperacetazine in ambulatory chronic schizophrenic patients". Current Therapeutic Research, Clinical and Experimental. 16 (2): 124–129. PMID   4156665.
2. Eslami Shahrbabaki M, Dehnavieh R, Vali L, Sharafkhani R (October 2018). "Chlorpromazine versus piperacetazine for schizophrenia". The Cochrane Database of Systematic Reviews. 10 (10): CD011709. doi: 10.1002/14651858.CD011709.pub2 . PMC   6517193 . PMID   30378678.